Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
100 hedge funds and large institutions have $714M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 18 reducing their positions, and 14 closing their positions.
638% more call options, than puts
Call options by funds: $72.7M | Put options by funds: $9.85M
183% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 18
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
32% more capital invested
Capital invested by funds: $541M → $714M (+$173M)
20.75% more ownership
Funds ownership: 55.69% → 76.44% (+21%)
11% more funds holding
Funds holding: 90 → 100 (+10)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$79.7M |
| 2 |
Janus Henderson Group
London,
|
+$72.2M |
| 3 |
BlackRock
New York
|
+$22M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$19.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$48.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.1M |
| 5 |
VMI
VHCP Management II
New York
|
-$9.81M |
BHVN Hedge Fund Activity: Q1 2018 in Review
100 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2018, worth a combined $714M — up 32% from $541M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BHVN positions and 14 closed out — a net gain of 10 holders — while 51 added to existing stakes and 18 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $79.7M. The largest seller was RA Capital Management, cutting an estimated $48.8M.
- 100 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2018, up from 90 in Q4 2017.
- Funds reported $714M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2018, up 32% quarter-over-quarter.
- 24 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2018 and 14 closed out, a net change of +10 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2018 was Perceptive Advisors, an estimated $79.7M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2018 was RA Capital Management, an estimated $48.8M sold.
Based on aggregated 13F filings for Q1 2018.